Maria S. Gawryl
No más puestos en curso
Perfil
Dr. Maria S.
Gawryl, MD PhD, is Vice President-Regulatory Affairs & Quality at Tetraphase Pharmaceuticals, Inc.
Dr. Gawryl was previously employed as VP-Clinical Development & Regulatory Affairs by EnVivo Pharmaceuticals, Inc., an Assistant Professor by Rush Medical College, a Principal by Baxter International, Inc., a Principal by GTC Biotherapeutics, Inc., a Principal by RenaMed Biologics, Inc., and Senior Vice President-Research & Development by Biopure Corp.
She received her undergraduate degree from Antioch College and a doctorate degree from the University of Connecticut.
Antiguos cargos conocidos de Maria S. Gawryl.
Empresas | Cargo | Fin |
---|---|---|
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Public Communications Contact | 17/10/2013 |
TETRAPHASE PHARMACEUTICALS, INC. | Consejero General | - |
BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | - |
REVO BIOLOGICS INC | Corporate Officer/Principal | - |
Rush Medical College | Corporate Officer/Principal | - |
Formación de Maria S. Gawryl.
University of Connecticut | Doctorate Degree |
Antioch College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
BAXTER INTERNATIONAL INC. | Health Technology |
Empresas privadas | 5 |
---|---|
Biopure Corp.
Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Health Technology |
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Health Technology |
RenaMed Biologics, Inc.
RenaMed Biologics, Inc. Medical/Nursing ServicesHealth Services RenaMed Biologics, Inc. provided clinical cellular therapy. The company was founded by H. David Humes, James P. Sherblom and Richard A. Andrews in 1995 and was headquartered in Lincoln, RI. | Health Services |
rEVO Biologics, Inc.
rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Maria S. Gawryl